$1.32 Billion Pledged for Translational Research in UK - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

$1.32 Billion Pledged for Translational Research in UK

ePT--the Electronic Newsletter of Pharmaceutical Technology

The UK government announced that a record £800 million ($1.32 billion) in funding would be set aside for translational research to boost the development of medicines, treatments, and care for patients, particularly in the fields of cancer, diabetes, and heart disease. Additionally, four new biomedical research units, which specialize in dementia research, will receive awards.

The investment will help develop National Health Service (NHS) and university partnerships through the National Institute for Health Research (NIHR) in a program that is scheduled to run for five years. The NIHR more broadly provides the framework in which the research infrastructure of the NHS in England is positioned, maintained, and managed as a national research facility.

The 31 awards announced today will go to partnerships with industry and charities, aiding in the development of the country’s science and research base, and securing the UK as a world leader in health research.

According to Prime Minister David Cameron, “A strong competitive science and research base is a crucial part of securing sustainable economic growth and creating jobs of the future, and we have some of the best scientists and facilities in the world. This investment will help ensure we continue to be at the cutting edge.”

Health Secretary, Andrew Lansley added, “As part of our £4 billion ($6.6 billion) investment in [R&D], we have committed £800 million for translational research – developing exciting new science into tangible, effective treatments that can be used across the NHS.”

There is an emphasis on “translational research” and a clear expectation that the funding should drive scientific research through to actual patient benefits. “By focusing on translational research across a wide range of diseases, the centers and units will help pull new scientific discoveries into benefits for NHS patients. I believe they will make a significant impact on the health of the population,” said Professor Dame Sally Davies, chief medical officer.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here